Market news

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Co...

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)

QATS is not a registered broker-dealer or investment advisor. All strategies are created and managed by users. Trading involves risk, and past performance is not indicative of future results. QATS does not store or manage user funds. All trades are executed via official broker APIs. Users must be 18 years or older to use the platform.

Maurizio Vitalle 3

© 2026 Quant Algorithm Tree System Ltd.

A better experience starts with cookies

Your data, your choice. We use cookies to improve how things work here.

Cookie policy